Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024
Shots:
- Bayer has highlighted the data from expansion part of P-I/II (SOHO-01) trial assessing the safety, tolerability, PK & efficacy of BAY 2927088 (20mg, BID, oral, reversible TKI) to treat HER2-mutant NSCLC at WCLC 2024
- In patients with advanced NSCLC & HER2-activating mutations, 43/44 were efficacy evaluable. The confirmed ORR was 72.1% [2.3% (1) CR], mDoR of 8.7mos. & PFS was 7.5mos. Patients with HER2 YVMA insertions had a 90% ORR, 9.7mos. DoR & 9.9mos. PFS
- Bayer has also recruited the first patient in global P-III (SOHO-02) study evaluating the efficacy & safety of BAY 2927088 as a 1L treatment for advanced NSCLC with activating HER2 mutations
Ref: Bayer | Image: Bayer
Related News:- Bayer Reports the Initiation of P-III (SOHO-02) Study of BAY 2927088 to Treat Non-Small Cell Lung Cancer (NSCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
